Kairos Pharma Ltd (KAPA)

$0.61 +0.05 (9.63%)
Market Cap 12.61M
Revenue (ttm) 0.00
Net Income (ttm) -2.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 862,500
Avg Vol 615,052
Day's Range N/A - N/A
Shares Out 20.82M
Stochastic %K 31%
Beta 2.27
Analysts Strong Sell
Price Target $8.33

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 948 2356
Address:
2355 Westwood Boulevard, Suite 139, Los Angeles, United States
GIPARK
GIPARK Feb. 28 at 4:31 AM
$KAPA when is fast track
0 · Reply
StormSurgeX
StormSurgeX Feb. 27 at 6:09 PM
~@SqueezeSharkie is operating at a level that clearly sets him apart from most traders in this space. If you’re serious about improving your decision-making and refining your edge, he’s worth following. There’s no cost, just consistent insights backed by performance. $KAPA $FBLG $NCT.X $XRAY • on watch
0 · Reply
Geo1313
Geo1313 Feb. 27 at 4:57 PM
$KAPA $KLAR $HUT $SLS
0 · Reply
Mega_Moons
Mega_Moons Feb. 27 at 4:56 PM
Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $KAPA $KLAR $HUT $SLS Close
0 · Reply
Mega_Moons
Mega_Moons Feb. 27 at 3:59 PM
Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $FUBO $SOC $DNA $KAPA Sure
0 · Reply
TraderBuckNKY
TraderBuckNKY Feb. 27 at 3:27 PM
$KAPA compared to yesterday's p/d...there's no volume here. Maybe a fake-out?...Careful.
2 · Reply
ezcheezie
ezcheezie Feb. 27 at 12:10 PM
$KAPA Loaded more after that gift of a dip.
0 · Reply
joaneegell
joaneegell Feb. 27 at 1:39 AM
$KAPA annnnnnd back down to bullshit. if you’re new here don’t listen to the pumpers. this company is a joke and you WILL lose your ass.
0 · Reply
ezcheezie
ezcheezie Feb. 26 at 11:16 PM
$KAPA Overnight volume will be interesting if the last 2 nights are any sort of an indicator.
2 · Reply
jamestocklover
jamestocklover Feb. 26 at 10:49 PM
$ENSC HUUUGGGGE ACCUMULATION TOWARD THE FLOAT LOCK. VERY THIN PATH TO $1+💥🚀💯 $BTOC 👀 $ZTEK 👀 $RXT 💥 $KAPA 👀
0 · Reply
Latest News on KAPA
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Feb 26, 2026, 7:00 AM EST - 3 days ago

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

Jan 20, 2026, 8:00 AM EST - 5 weeks ago

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Dec 17, 2025, 8:15 AM EST - 2 months ago

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Kairos Pharma Provides Shareholder Update

Nov 4, 2025, 8:00 AM EST - 4 months ago

Kairos Pharma Provides Shareholder Update

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 20, 2025, 8:00 AM EDT - 4 months ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 18, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 11, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 3, 2025, 8:15 AM EDT - 6 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 6 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 28, 2025, 12:28 PM EDT - 7 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 16, 2025, 8:30 AM EDT - 8 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 2:08 PM EDT - 8 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jul 15, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Jun 3, 2025, 8:15 AM EDT - 9 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 10 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Apr 17, 2025, 8:00 AM EDT - 11 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 18, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 11, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Feb 6, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 28, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Jan 7, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 26, 2024, 7:51 AM EST - 1 year ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 16, 2024, 12:15 PM EST - 1 year ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Kairos Pharma Prices $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma Files For U.S. IPO

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

GIPARK
GIPARK Feb. 28 at 4:31 AM
$KAPA when is fast track
0 · Reply
StormSurgeX
StormSurgeX Feb. 27 at 6:09 PM
~@SqueezeSharkie is operating at a level that clearly sets him apart from most traders in this space. If you’re serious about improving your decision-making and refining your edge, he’s worth following. There’s no cost, just consistent insights backed by performance. $KAPA $FBLG $NCT.X $XRAY • on watch
0 · Reply
Geo1313
Geo1313 Feb. 27 at 4:57 PM
$KAPA $KLAR $HUT $SLS
0 · Reply
Mega_Moons
Mega_Moons Feb. 27 at 4:56 PM
Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $KAPA $KLAR $HUT $SLS Close
0 · Reply
Mega_Moons
Mega_Moons Feb. 27 at 3:59 PM
Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $FUBO $SOC $DNA $KAPA Sure
0 · Reply
TraderBuckNKY
TraderBuckNKY Feb. 27 at 3:27 PM
$KAPA compared to yesterday's p/d...there's no volume here. Maybe a fake-out?...Careful.
2 · Reply
ezcheezie
ezcheezie Feb. 27 at 12:10 PM
$KAPA Loaded more after that gift of a dip.
0 · Reply
joaneegell
joaneegell Feb. 27 at 1:39 AM
$KAPA annnnnnd back down to bullshit. if you’re new here don’t listen to the pumpers. this company is a joke and you WILL lose your ass.
0 · Reply
ezcheezie
ezcheezie Feb. 26 at 11:16 PM
$KAPA Overnight volume will be interesting if the last 2 nights are any sort of an indicator.
2 · Reply
jamestocklover
jamestocklover Feb. 26 at 10:49 PM
$ENSC HUUUGGGGE ACCUMULATION TOWARD THE FLOAT LOCK. VERY THIN PATH TO $1+💥🚀💯 $BTOC 👀 $ZTEK 👀 $RXT 💥 $KAPA 👀
0 · Reply
jamestocklover
jamestocklover Feb. 26 at 10:45 PM
$ENSC GETTING BIGGER. SOON .60 BREAK, THEN $1+. PURE ACCUMULATION TOWARD THE FLOAT LOCK💥🚀💯 $BTOC 🔥 $ZTEK 🔥 $KAPA 👀 $IMTE 👀
0 · Reply
jamestocklover
jamestocklover Feb. 26 at 10:16 PM
$ENSC GETTING READY FOR .50 BREAK, THEN MULTIBAGGER💥🚀💯 $KAPA 🔥 $ZTEK 🔥 $BTOC 🔥 $QH 👀
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz Feb. 26 at 8:03 PM
$KAPA reason for decline is because new assets not needed hardly any cash. They need worry about the drug they have ENV-105
3 · Reply
KeeperGreen
KeeperGreen Feb. 26 at 7:51 PM
$KAPA Another garbage company I hope they delist this pump and dump company
1 · Reply
Mrmessiah
Mrmessiah Feb. 26 at 7:47 PM
$KAPA Grabbed a few here with a tight stop. Could see a bounce to .66
1 · Reply
Mrmessiah
Mrmessiah Feb. 26 at 7:37 PM
$KAPA Gross. Glad I got out. Might be a good scalp opportunity
1 · Reply
kenco27
kenco27 Feb. 26 at 7:29 PM
$KAPA this will be delisted
1 · Reply
Mega_Moons
Mega_Moons Feb. 26 at 6:02 PM
Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $FLNC $KAPA $TE $ENVX Soon
0 · Reply
ezcheezie
ezcheezie Feb. 26 at 4:28 PM
$KAPA Just an attention getter. See ya'll at 3$.
0 · Reply
Buyredselgreen
Buyredselgreen Feb. 26 at 3:42 PM
$KAPA kopa kepa kapi
0 · Reply
Fish69
Fish69 Feb. 26 at 3:09 PM
$KAPA dollar stock
0 · Reply
SupremeTrader93
SupremeTrader93 Feb. 26 at 2:57 PM
$QNCX 👀 can this go for a push towards .15 the .20?! 🔥👏 $CURX $ALBT $AEHL $KAPA
1 · Reply